The US FDA has ordered CTI BioPharma to halt a Phase III trial of a cancer drug candidate after patients died from “intracranial hemorrhage, cardiac failure and cardiac arrest.”
Under the President’s FY 17 proposed budget request, the FDA would receive $2.743bn in budget authority appropriations – and many are frustrated with the lack of funding.
Rondaxe Enterprises says CMOs can more accurately predict the cost of making customers drugs using its new software.
Crown Bioscience has expanded its portfolio of non-animal based disease models by licensing a range of cellular prostate cancer models developed by UK academics.
Lonza will make a candidate heart failure gene therapy for Renova Therapeutics under the second biomanufacturing deal it has signed this week.